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Abstract
The importance of surgical research has gained new prominence over the past decades as the
relevance of well designed and well conducted studies has become increasingly evident. There
are two basic but diametrically different methods of conducting research: the prospective ran-
domized clinical trial and the retrospective surgical outcomes study based on administrative data.
Administrative databases contain data that were initially collected for purposes other than sci-
entific research. Whereas the prospective randomized clinical trial is familiar to most surgeons,
surgical outcomes research based on administrative data constitutes a genre of investigation that
is often unfamiliar to and even disparaged by the surgical community. In the present article, the
strengths and weaknesses of both prospective randomized clinical trials and retrospective surgical
outcomes research are discussed. Specifically, the advantages and limitations of investigations
based on large administrative databases are outlined. Because both study designs play an
important role in surgical research, carefully designed and implemented surgical outcomes re-
search based on administrative data should be viewed as being complementary and not inferior to
prospective randomized clinical trials.
The subject here—outcomes research based onadministrative databases—begs the question:
goldmine or fool’s gold? Although ‘‘outcomes research’’
has become increasingly visible in the surgical literature
over the past few years, a clear definition is still lacking,
and descriptions of ‘‘outcomes research’’ are numerous1
and often confusing. Outcomes research includes a
variety of study types, including traditional clinical re-
search (prospective randomized clinical trials, cohort
studies, case-control studies, case-series)1 as well as
volume-outcomes research, small-area analyses, trends
analyses, access to health care investigations, cost-
effectiveness studies, and quality of life research.2 The
overall objective of surgical outcomes research is to
assess the effectiveness, appropriateness, and costs of
surgical care.1,3
Outcomes research based on secondary or adminis-
trative data represents a specific subset of clinical re-
search. Administrative data have been defined as ‘‘large,
computerized data files generally compiled in billing for
health care services such as hospitalizations.’’4 There-
fore, administrative data contain information that were
primarily collected for purposes other than scientific re-
search (e.g., billing).5,6 Herein I use the terminology
‘‘secondary database’’ as a synonym for ‘‘administrative’’
database.
Surgical outcomes research based on administrative
data has a number of important advantages compared
with randomized clinical trials. First, it is generally less
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SURGICAL OUTCOMES
costly and time-consuming, as the data are readily
available.5–8 Second, exclusion criteria are usually cho-
sen parsimoniously, and thus the generalizability of the
findings of outcomes research studies may exceed that of
tightly controlled randomized trials.9 Hence, the issue of
selection bias—owing to the population-based collection
of administrative data—is less problematic,2,9 and the
effectiveness, the actual benefit in the real world, of an
intervention can be assessed.10 This is in contrast to
prospective randomized clinical trials that evaluate a
procedure’s efficacy in highly selected populations under
ideal and somewhat artificial circumstances. Third, as
administrative databases contain often thousands or
even millions of patients, lack of power does not repre-
sent a threat to the analyses. Even the evaluations of
important outcomes in subsets (e.g., elderly patients,
women, children, patients with a specific tumor stage) or
assessments of rare diseases or infrequent endpoints
can usually be done with sufficient statistical power.9
Fourth, administrative databases allow the performance
of descriptive analyses.10 For instance, such databases
enable the approximate determination of patients with a
certain disease as well as the age, gender, and race
distribution of these patients. Administrative databases
also allow comparison of mortality, morbidity, or reoper-
ation rates among hospitals and regions.8 Finally, the
most important advantage of outcomes research is that it
enables researchers to answer relevant questions that
cannot be answered through a randomized clinical trial
because the latter would require prohibitively complex,
costly, or even ethically unacceptable practices.1
Herein I briefly describe some of the most important
subtypes of surgical outcomes research, including small-
area variations, volume-outcomes research, and access
to health care investigations. As shown below, adminis-
trative data can be well suited to perform such investi-
gations.
SMALL-AREA VARIATIONS OF SURGICAL
PROCEDURES
The primary objective of small-area analyses is to as-
sess differences in the use of surgical procedures among
various geographic regions. If relevant differences are
found, it is likely that certain areas are underserved
whereas others may be experiencing overutilization of
surgical procedures.
More than 30 years ago, Wennberg and colleagues
performed pioneering work in small-area analyses. Their
ground-breaking study assessed whether differences
existed in the use of a variety of surgical procedures in
different regions of Vermont.11 They found striking dis-
crepancies in the age-adjusted rates for nine frequently
performed surgical procedures. The most important dif-
ference was observed for tonsillectomy, which ranged
from 13 cases to 151 cases per 10,000 persons. Building
on Wennberg’s work, numerous investigations have
shown large discrepancies in the use of surgical proce-
dures for breast cancer,12,13 back pain,14 colorectal
cancer,15 knee arthroplasty,16 tonsillectomy, hemorrhoi-
dectomy, hysterectomy, and prostatectomy during the
past few decades.17
Administrative data are useful in the performance of
small-area variation studies. In one investigation, Nattin-
ger and associates18 used Medicare administrative data
to assess variations in the use of breast-conserving sur-
gery among 36,982 women with breast cancer in various
states of the United States. The authors found consid-
erable differences (ranging from 3.5% to 21.2%) in the
use of breast-conserving therapy among different U.S.
states. Nattinger et al. concluded that this variation in the
use of breast-conserving treatment could not be ex-
plained by differences in hospital characteristics.
Area variations analyses of surgical procedures have
significant potential in surgical research, as they allow the
identification of large differences in surgical practice.
These differences are partially attributable to a lack of
consensus among surgeons and to uncertainty regarding
the effectiveness or appropriateness of a given proce-
dure.11,17,19 These analyses have proven useful in stim-
ulating surgeons to reflect critically on the reasons for the
existing differences and may help establishing a con-
sensus regarding the indication for a surgical intervention.
This not only may result in decreased health care costs
but, more importantly, may lead to tremendous patient
benefit.
For instance, investigations have shown that a be-
tween-area variation in the use of breast-conserving
therapy has stimulated a decrease of the rate of mas-
tectomy performances in breast cancer patients, although
differences persist.20 Indeed, the diffusion of certain
guidelines appears to be faster in teaching hospitals,
large hospitals, and urban areas.20,21
VOLUME OUTCOMES ANALYSES
Volume outcomes analyses assess whether surgeons
or hospitals with high case loads have better outcomes
than do low-volume providers. Although this hypothesis
seems intuitive, the association between higher volumes
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and better outcomes for certain procedures has been a
matter of great debate for many years.
One of the most important and most widely referenced
volume outcomes investigations was performed by
Birkmeyer and colleagues.22 Based on Medicare data
that includes approximately 2.5 million procedures, they
assessed whether high hospital volume was associated
with decreased mortality for six cardiovascular proce-
dures and eight types of cancer resection. Differences in
sociodemographics and risk factors between the hospital
volume categories were adjusted for in multivariable
analyses. The authors found diminished mortality with
increasing hospital volume for all 14 surgical procedures.
Based on these findings, Birkmeyer et al. concluded that
patients undergoing cardiovascular or cancer procedures
can significantly decrease their mortality by selecting a
high-volume hospital. A variety of other analyses based
on secondary data have shown that higher volume was
inversely related to lower mortality for pancreatectomy,
colorectal surgery, esophagectomy, liver resection, pro-
statectomy, lung or bronchial tumor resection, and pelvic
exenteration.23–29
In a recent investigation based on the Nationwide
Inpatient Sample 1997,30 we assessed whether patients
with rectal cancer are more likely to undergo sphincter-
sparing procedures versus abdominoperineal resection if
operated on by high-volume versus low-volume sur-
geons. We found a risk-adjusted odds ratio that ex-
ceeded 5 (patients operated on by high-volume
surgeons were more than five times more likely to un-
dergo sphincter-sparing procedures than were patients
who were operated on by low-volume surgeons). As we
were unable to risk-adjust for tumor size, tumor stage,
and grading because these parameters could not be
ascertained from the Nationwide Inpatient Sample, pa-
tient selection could in part explain the differences in
performing sphincter-sparing procedures. Nonetheless,
we believe that the important difference (risk-adjusted
odds ratio exceeding 5) of undergoing sphincter-sparing
procedures between high- and low-volume surgeons
cannot be explained solely by residual confounding.
However, because investigations based on administra-
tive data are best suited for generating hypotheses, a
similar investigation with ‘‘real’’ data that contain poten-
tial confounders would be warranted. This would help
confirm the hypothesis that patients may decrease the
risk of undergoing abdominoperineal resection associ-
ated with definitive colostomy if they are operated on by
high-volume surgeons.
It is noteworthy that the relation between higher volume
and improved outcomes should not be assumed auto-
matically. Although this relation is now generally accepted
for high-risk procedures, it remains unclear whether it ap-
plies equally to low-risk surgery. High volume represents a
surrogate marker for outcomes and thus cannot neces-
sarily be taken as an indicator of quality. Furthermore, al-
though regionalization is justified for high risk procedures, it
is obvious that, for logistical reasons, not all procedures
can be performed in highly specialized centers.
ACCESS TO HEALTH CARE
Equality in health care utilization has become an
increasingly important issue for health services research
over the past decade. Racial31–33 and socioeconomic32
differences have been identified as independent factors
for inequality of access to health care. In cancer patients,
several investigations reported that African American
patients receive less intensive treatment or have poorer
outcomes for breast,34 prostate,35 colon and rectum,36,37
bladder, and lung32,38 cancer. It is clear that well de-
signed studies that reveal potential socioeconomic or
racial discrepancies in access to health care are of
greatest importance to the medical community, policy-
makers, and the general public.
For obvious reasons, however, access to health care
cannot be assessed in a randomized clinical trial. We
then see that surgical outcomes research complements
the randomized clinical trial in this regard, as outlined in
two examples.
First, Cooper and colleagues identified predictors
associated with patients undergoing potentially curable
surgical therapy for resectable colorectal cancer, basing
their research on a large administrative database that
included 81,579 Medicare beneficiaries.37 The authors
found that African Americans were significantly less likely
to undergo potentially curative surgery than were white
patients (78% vs. 68%, P < 0.001). This difference re-
mained statistically significant even after controlling for
age, co-morbidity, and location and extent of the tumor.
Also, African Americans had a significantly higher mor-
tality rate than white patients, even in multivariable and
subset (teaching versus nonteaching, private versus
public) analyses.
Second, in a recent study, our group39 investigated
whether private insurance status and race represented
independent predictors for undergoing laparoscopic
appendectomy in patients with appendicitis. Patients
(n = 145,456) with primary ICD-9 procedure codes for
laparoscopic and open appendectomy were selected
from the 1998, 1999, and 2000 Nationwide Inpatient
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Samples. Even after adjusting for potential confounders
such as age, gender, the patient’s co-morbidity and
median zip code income, hospital location and teaching
status, and presence of appendiceal abscess or perfo-
ration, privately insured patients and white patients were
significantly more likely to undergo laparoscopic surgery
than were African Americans and Medicaid patients.
TREND ANALYSES
Administrative data may be well suited for trend anal-
yses. Often, nationwide or statewide administrative data
have been collected for several years or even decades,
allowing evaluation of a change over time.
A good example of the use of administrative data for
trend analyses was provided by Flum and colleagues.40
They used the Washington state hospital discharge
database and the U.S. Census Bureau data for 1987–
1998 to evaluate whether misdiagnosis of appendicitis
has declined with increasing use of diagnostic tools such
as computed tomography (CT) scans and ultrasonogra-
phy. The analysis included 63,707 nonincidental appen-
dectomy patients. Among them, 84.5% had appendicitis
and 15.5% had no diagnosis of appendicitis. Interestingly,
the percentage of misdiagnosed appendicitis did not
change over time, implying that the correct diagnosis of
appendicitis has not significantly improved with more




Whereas surgical outcome studies usually assess
questions regarding the distribution and effects of health
care provided to average persons in typical clinical
practice, randomized clinical trials measure the relative
efficacy of a treatment in highly selected patient samples
under ideal and somewhat artificial circumstances.
Therefore, the objectives of the randomized clinical trial
and surgical outcomes research based on administrative
data are often different, and there is usually not a choice
of whether to use one design or the other. Rather, the
research question determines which study type should be
used. However, an overlapping area between random-
ized clinical trials and surgical outcomes research is the
comparison of two surgical procedures. In an investiga-
tion from our group, laparoscopic versus open appen-
dectomy were compared using the Nationwide Inpatient
Sample 1997, an administrative database with patient
discharges from various states across the United
States.41 A total of 43,757 patients were included in the
investigation; and outcomes such as in-hospital morbid-
ity, in-hospital mortality, length of hospital stay, and the
rate of routine patient discharge were assessed. We
found the laparoscopic procedure to be advantageous
over the open procedure for these outcomes.
Interestingly, Benson and Hartz compared infection
rates after laparoscopic and open appendectomy be-
tween published prospective randomized clinical trials
and observational studies. The authors found similar
results for the two study types.42
CAVEATS OF USING ADMINISTRATIVE
DATABASES
Limited Clinical Data Availability
It is clear that administrative databases have several
inherent limitations and drawbacks. Administrative data-
bases are usually established to serve billing purposes
but not to answer specific research questions. Therefore,
the amount of clinically relevant data in administrative
databases may be limited.7,8,43,44 For instance, informa-
tion regarding disease severity, tumor size, lymph node
status, and grading may be missing. It is thus critically
important to consider whether between-group differences
of those parameters affect the study findings and
conclusions. For instance, in the above-mentioned vol-
ume-outcomes study,22 a variety of putative confounding
factors were not adjusted for in the multivariable analysis,
as they could not be ascertained from the administrative
database used. Nonetheless, Birkmeyer and col-
leagues22 concluded that the mortality differences
observed between low- and high-volume providers could
not be explained by unmeasured confounding alone.
Similar to putative confounders, administrative data-
bases do not contain certain important endpoints, such as
postoperative quality of life and functional status.8
Nonetheless, length of hospital stay, postoperative mor-
bidity, postoperative mortality, and rate of reoperation can
be ascertained from many administrative databases.
These are relevant outcomes that allow important re-
search questions to be addressed and have the potential
to affect surgical practice.
Miscoding, Undercoding, and DRG Creep
The data of administrative databases may be inaccurate,
first, because of miscoding or undercoding.7,15,43,45–50
There are various reasons that may lead to miscoding, as
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the medical record is nowadays increasingly used for cost
containment, legal, or administrative purposes.6 Thus the
medical record may in fact not reflect the actual health
status of the patient.
Second, overcoding has been described as a potential
source of distortion of administrative data.51 For instance,
if hospitals are reimbursed based on the complexity of the
patient’s disease, there may be a tendency for overcod-
ing primary and secondary diagnoses, a phenomenon
called diagnosis-related group (DRG) creep.51 Miscoding
represents an inherent limitation that must be carefully
considered when interpreting the findings of studies
based on administrative data.
Data Mining
Research based on administrative data should be
hypothesis-driven. It is critically important that, similar to a
randomized clinical trial, an a priori hypothesis is stated.
Then, one should ascertain whether an administrative
database is well suited to test this a priori hypothesis. When
interpreting an investigation based on administrative data,
it is essential to make the distinction between hypotheses
that were created prior to performing the study (a priori
hypothesis) and hypotheses that were stated after the
study was conducted (a posteriori hypothesis). A priori
hypotheses do not carry the risk that the investigator was
influenced by the readily available data and thus are less
prone to generating erroneous conclusions. If hypotheses
are stated a posteriori, it is possible that the investigator
looked at various patient subsets until he or she found
significant results. This phenomenon is often referred to as
‘‘data mining,’’ ‘‘data dredging,’’ or a ‘‘fishing expedition’’;
and it has an inherent increased risk of a type I error
(obtaining a false-positive finding).52 Investigations that
formulate their hypotheses after the study has been con-
ducted should be viewed as hypothesis-generating rather
than hypothesis-testing, and even more so if they examine
patient subsets and perform multiple comparisons.52,53 If
an investigator performs multiple comparisons, the
threshold of statistical significance (usually set at 0.05)
should be adjusted for using the Bonferroni or other sta-
tistical method to decrease the risk of a type I error.52 For
instance, if three independent hypotheses are tested, the
threshold of statistical significance should be lowered to
0.05:3.00 (= 0.017).
Statistical Significance versus Clinical
Relevance
As administrative databases can contain up to several
million patients, with even extracted patient samples
potentially being large, it is essential to differentiate be-
tween statistical significance and clinical relevance. If the
sample size is large, even tiny differences between study
groups become statistically significant.52 The question,
however, is whether these small differences are clinically
relevant. A clinically relevant difference is associated with
a change in health care that represents a meaningful
improvement to the patient. It is thus critically important to
consider the absolute results of an analysis based on
large administrative databases, as they may be clinically
irrelevant despite being statistically significant.
Confounding
Prior to defining a confounding variable it is important to
understand the meaning of, and the association between, a
predictor variable and an outcome. Commonly, studies are
designed to show a link between a predictor variable
(independent variable) and an outcome (dependent vari-
able). Predictor variables can be either a diagnostic or
therapeutic intervention (e.g., new surgical therapy, new
diagnostic procedure) or a risk/prognostic factor such as
age, patient co-morbidities, tumor size, or lymph node
status.52 Frequently assessed outcomes in the surgical
literature are disease-free survival, overall survival, re-
sponse to a treatment, and postoperative morbidity. A
confounding variable (also known as a confounding factor
or confounder) is an extrinsic factor that is linked to the
predictor variable and also affects the outcome. The per-
ceived association between the predictor and the outcome
variable is distorted because of the confounder.52 Also a
confounder cannot be an intermediate in the causal path-
way between exposure and outcome.54 Because of the
nonrandomized study design of retrospective outcomes
research, the results must be adjusted for potential con-
founding factors using multivariable analyses (or other
statistical techniques, such as propensity score analyses
or an instrumental variable method) to minimize bias.55 It is
clear that bias cannot be perfectly adjusted for, as some
known confounders may not be in the database. Moreover,
although it is possible to risk-adjust for known confounders
if available in the database, researchers cannot control for
unknown confounding. Nonetheless, as pointed out by
Birkmeyer and colleagues,22 if the differences are large
even after adjusting for putative confounding factors, it can
be assumed that they cannot be explained solely by
residual or hidden confounding.
Because of these inherent limitations and drawbacks, it
is important to interpret and scrutinize critically the
surgical outcomes research based on administrative data
prior to incorporating the studies‘ recommendations into
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clinical practice. Also, efforts must be undertaken to im-
prove the accuracy of administrative databases even
further, which makes them an even more valuable tool for
assessing outcomes and quality of care. However, most
of the above-mentioned investigations have been per-
formed with greatest attention to scientific rigor and are of
clear relevance to the medical community despite being
based on administrative data. It must be concluded
that—if well designed and well conducted—administra-
tive databases are goldmines for surgical research rather
than fool’s gold.
CHALLENGES WHEN PERFORMING
CLINICAL TRIALS IN SURGERY
It is generally agreed that randomized clinical trials,
when designed and conducted properly, provide the
highest standards of scientific evidence and are consid-
ered the gold standard for evaluating the efficacy of
therapies.56–59 By randomly assigning patients to either
the experimental arm or the control arm, the investigator
can control for extraneous factors (confounders). In
contrast to nonrandomized studies, random allocation
allows controlling for both known and unknown con-
founders. Theoretically, the only difference between the
two groups is the intervention (A versus B). Thus, the
investigator is better able to demonstrate the causal link
between the intervention and the endpoints under
investigation.60 Despite the obvious advantages and
strengths of randomized clinical trials in surgery, they are
complex, costly, and time-consuming undertakings.
Many surgeons believe that every prospective ran-
domized study is bias-free. This belief is not in fact re-
flected in reality, as poorly designed and conducted
randomized trials provide distorted, confounded results
that are not useful for improving current surgical practice.
I have herein summarized the particular challenges that
pertain to the performance of prospective randomized
clinical trials in surgery.
Patient Accrual and Clinical Equipoise
Unless a randomized clinical trial is performed for
common diseases, recruiting a sufficient number of pa-
tients in a timely manner is often difficult. For instance,
performing a single-institution trial for adrenal or rare
thyroid cancer might not be feasible, as the number of
patients with the disease under investigation is prohibi-
tively small. Equally important, patients often do not want
to be randomized.61 They may be reluctant to have ran-
dom chance decide into which arm they go. Similarly,
surgeons often do not want to randomize their patients,
as they frequently believe that one therapeutic option is
better than the other. This phenomenon is referred to as
lack of clinical equipoise. Equipoise represents a state of
uncertainty regarding the benefits of alternative treat-
ments.62 The lack of clinical equipoise is prevalent in the
surgical community and represents a challenging factor
when performing surgical clinical trials. Thus it is critically
important that the investigators emphasize to patients
and physicians that the premise of a randomized clinical
trial is based on the absence of current scientific evidence
that the experimental arm is superior to the control arm.
Furthermore, to facilitate patient accrual and increase the
feasibility of the study, one should consider the option of
performing a multicenter trial for rare diseases.
Selection Bias, Generalizability of Results, and
‘‘Pragmatic Trials’’
Most randomized controlled trials have clearly defined
inclusion and exclusion criteria, are based on a relatively
homogeneous patient population,63 and are performed
under somewhat artificial and controlled conditions.1,64
Moreover, only a small percentage of potentially eligible
patients agree to participate in surgical randomized clin-
ical trials.64 This phenomenon is accentuated in ran-
domized controlled trials in surgical oncology, for which it
is estimated that less than 3% of cancer patients partici-
pate.65 However, it is well known and extensively docu-
mented in the literature that patients who agree to
participate in randomized clinical trials are systematically
different from patients who do not participate.58,64 Pa-
tients in clinical trials are, on average, healthier, more
compliant, and enjoy higher socioeconomic status,58,64
resulting in a selection bias of unknown magnitude. Thus
even if an intervention works in the somewhat artificial
setting of a randomized clinical trial, it is unclear whether
it will have the same benefit in the ‘‘real world,’’1,2,58,63 as
numerous examples in the medical literature have dem-
onstrated. Also, it is clear that the findings of a
randomized clinical trial cannot be extrapolated to patient
populations that were excluded from the study. For in-
stance, if a surgical intervention was shown to have sig-
nificant overall survival advantage in male Caucasians
with stage I/II disease, aged 40 to 55 years, the results
cannot be generalized to women, patients with advanced
stage disease, African Americans, Hispanics, Asians, or
the elderly. Therefore exclusion criteria must be dis-
cussed carefully during the planning phase of a trial and
260 Guller: Outcomes Research versus Randomized Trials
should be chosen parsimoniously.64,66 Clearly, the more
stringent the exclusion criteria, the greater is the selection
bias and the less generalizable are the results.
The performance of ‘‘pragmatic trials’’ may help
diminish selection bias. Pragmatic trials aim to reflect the
real-world situation as much as possible and often eval-
uate a range of outcomes, including cost-effectiveness
and quality of life aspects in addition to the clinical end-
points.67 Exclusion criteria are chosen parsimoniously in
the design of pragmatic trials, and patients are always
analyzed in the initially assigned treatment group (inten-
tion-to-treat analysis).68 The strength of pragmatic trials
lies in providing patients and health care providers with
information regarding the effectiveness of treatment op-
tions in routine clinical practice.68,69
Sample Size, Follow-up, and Costs
One of the most unambiguous and frequently used
primary endpoints in surgical clinical trials is overall
survival, as it is a wholly objective criterion. However,
because the surgical treatment is often studied in early-
stage disease where surgical therapy is most beneficial,
the evaluation of overall survival generally requires a long
follow-up70 period, which is associated with increased
logistical difficulties and higher costs. Furthermore, the
longer the follow-up, the higher is the drop-out rate, which
again increases the number of patients required in a
prospective randomized trial. To shorten the follow-up
period, the assessment of surrogate endpoints (i.e.,
endpoints believed to be linked to clinical endpoints, such
as overall survival) has been suggested. The advantage
of using surrogate endpoints is that they can be evaluated
at an earlier point in time than the clinical endpoint,
shortening the time required for the trial.70–72 However,
numerous investigations have shown that surrogate
endpoints (e.g., tumor growth or increase in a tumor
marker) are fallacious.70,73
Lack of Power, Type II Error, and Effect Size
Power is defined as the probability of finding a statis-
tically significant result (of rejecting the null hypothesis) in
a study if the populations are truly different.74,75 A type II
error (synonym: beta) represents the situation in which
the results lead to the erroneous conclusion that there is
no significant difference between the study groups when
in reality a difference exists.52,74 Beta, the false-negative
rate, is complementary to the power of a study.
The choice of adequate power in a randomized clinical
trial is critical, as investigators and funding agencies must
be confident that an existing difference in the overall
patient population can be detected using the study sam-
ple. The power of a study depends on various factors: the
effect size (expected difference in the primary outcome
between the study groups, see below), the chosen type I
error (rate of false-positive results), and the precision
(e.g., standard deviation) of the primary outcome under
investigation.74 Moreover, the power of a study is intrin-
sically linked to the sample size. The larger the sample
size, the higher is the power. The importance of sample
size consideration is clear: Even the most thoroughly
planned and well executed randomized clinical trial may
fail to answer the research question if the sample size is
too small. Often small studies do not find statistically
significant differences. It is then unclear whether there
was truly no difference between the treatment options or
the sample size was prohibitively small to provide suffi-
cient evidence for a statistically significant difference.74
Unfortunately, there is a plethora of randomized clinical
trials in the surgical literature that were clearly under-
powered while claiming that there was no statistically
significant difference in outcomes,76–78 an erroneous and
potentially harmful conclusion.
For sample size computations, investigators start by
defining a clinically meaningful difference in the primary
outcome (e.g., overall survival) between treatment A and
B (called effect size, or delta), which is believed to be true
for the overall patient population. The effect size is often
the ‘‘least important difference in outcomes’’ that would
lead to a change in current clinical practice.79 The smaller
the expected difference in the outcome, the larger the
required sample size must be.74
As a result of the difficulties of patient accrual, the high
costs associated with prospective randomized trials in
surgery, limited funding, or undertraining, the estimates
on which the sample size for a randomized clinical trial is
based might be too optimistic (e.g., choosing a too large
effect size), and thus the resulting sample size is too
small or, worse, no sample size was computed at all.
Moreover, even if the sample size of a randomized clini-
cal trial provides sufficient power to assess the primary
endpoint, it is still too small to perform relevant subset
analyses. For instance, it may be important to know
whether an intervention has particular benefits in the el-
derly, in women, or for a specific disease stage.
Another challenging issue in the interpretation of ran-
domized clinical trials that enrolled patients with early-
stage disease with good prognosis is the estimation of the
real treatment effect if there are few events. For instance,
one might claim that a surgical procedure is safe because
there were no deaths among 20 patients undergoing
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surgery.80 This may, however, not be true and is difficult
to gauge for the reader if 95% confidence intervals are not
provided in the manuscript.
A simple aid in the interpretation of such results is ‘‘the
rule of 3’’ for zero numerators: If an outcome (e.g., death)
occurs 0 times in n patients, the upper 95% confidence
limit is approximately 3/n.80,81 In the example above, the
upper 95% confidence limit would thus be about
3/20 = 0.15, or 15%. In other words, based on the sample
of 20 patients, one can be 95% sure that the true mortality
rate for the surgical procedure lies between 0% and 15%.
Lack of Placebo Controls and Sham Surgery
An important difficulty in the design of surgical clinical
trials is the frequent lack of placebo controls (surgical
placebos, sham surgery). A surgical placebo represents a
simulated operation in which the skin incisions are done
without actually performing the operation. This makes the
blinded patient believe that he or she underwent surgery
which may be associated with a placebo effect. For in-
stance, Moseley et al. conducted a three-arm prospec-
tive, randomized, placebo-controlled trial in 180 patients
with osteoarthritis of the knee.82 Patients were assigned
to arthroscopic de´bridement, arthroscopic lavage, or
placebo surgery. The placebo surgery consisted of per-
forming a skin incision only, without inserting the arthro-
scope. Interestingly, outcomes after arthroscopic lavage
or arthroscopic de´bridement were not superior to those
seen with the sham surgery.
It is clear that the placebo-controlled randomized clin-
ical trial represents the most unbiased study design.
However, the controversy regarding sham surgery is
considerable, and therefore surgical placebos are rarely
used.79,83,84
Postrandomization Bias
One of the most important challenges when performing
clinical trials in surgery is postrandomization bias. Po-
strandomization bias is largely due to the impracticalities
of blinding during a surgical intervention. Single blinding
(blinding the patient to the arm assigned) is rarely pos-
sible,61 and double blinding (blinding both physician and
patient to the assigned arm) is even more difficult if the
intervention is a surgical procedure, a chemotherapy
regimen, or radiation therapy.
Postrandomization bias occurs in a multitude of forms,
one of which is ascertainment bias.66 Let us consider a
Phase III trial in which disease-free survival is evaluated
in esophageal cancer patients randomized to neoadju-
vant radiotherapy and surgery (arm 1) versus surgery
alone (arm 2). It can be hypothesized that patients as-
signed to arm 2 (surgery alone) believe that they should
undergo more stringent follow-up diagnostic procedures
as they did not receive radiation therapy. It can thus be
assumed that these patients see their primary care phy-
sicians more frequently, undergo more CT scanning,
upper endoscopies, and tumor marker assays among
other measures and that recurrences are diagnosed
earlier in this subset of patients than in the subjects who
were randomized to arm 1. In this scenario a between-
arm difference of disease-free survival could therefore be
linked to discrepancies in follow-up diagnostic procedures
even if the therapeutic options are equiefficient.
Similarly, patients who were randomized to surgery
alone might seek additional postoperative therapy (e.g.,
immunotherapy or alternative medical treatment options),
which again may affect the outcome under investigation.
This phenomenon is called co-intervention.66
Differences in surgical expertise may also affect the
outcomes under investigation.61 Let us consider a Phase
III randomized trial comparing open and laparoscopic
sigmoid resection for diverticular disease. It is possible
that patients who are randomized to the laparoscopic
procedure are operated on by the senior surgeon, who
has extensive experience in laparoscopic surgery and is
highly motivated to prove that the laparoscopic approach
is superior to the open procedure. Conversely, the patient
randomized to open colectomy is operated on by the
surgical resident, who certainly has less experience and
may lack the senior surgeon’s particular motivation. Al-
though randomization equally distributes both known and
unknown confounders (e.g., age, co-morbidity, gender,
race) to arm 1 and arm 2, there is a postrandomization
bias of unknown magnitude due to differences in surgical
expertise.
Another form of postrandomization bias is the ‘‘differ-
ential expertise bias.’’85 Differential expertise bias occurs
when unequal percentages of surgeons are experienced
in performing the standard versus the investigational
procedure.
Let us consider a different scenario of the trial ran-
domizing patients to open resection (arm 1) versus lap-
aroscopic sigmoid resection (arm 2). Currently, most
surgeons are better trained to perform the open proce-
dure, and a considerable percentage has either not yet
started to do laparoscopic sigmoid resection or is still
climbing the learning curve. Let us assume that 90% of
the patients in both study arms are operated on by
surgeons with excellent expertise in performing the open
resection but little experience in the laparoscopic proce-
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dure, and only 10% of patients are operated on by sur-
geons who are equally trained for both procedures. In this
scenario, the trial is biased toward the open procedure.
A multicenter randomized trial from The Netherlands
has shown that laparoscopic fundoplication produces
substantially worse results than the open procedure.86
This conclusion is somewhat counterintuitive, and it is
possible that the study was confounded by differential
expertise bias.
To minimize postrandomization bias in surgical clinical
trials, it is critically important to standardize the surgical
procedures and the diagnostic follow-up interventions as
much as possible. Equally important, all surgeons par-
ticipating in a clinical trial should have similar experience
and technical expertise. This can be guaranteed if each
participating surgeon is required to have performed a
certain number of cases (ensuring that the surgeons
overcome their learning curve) involving the relevant
procedure prior to participating in a randomized clinical
trial.
Alternatively, one could perform a surgical expertise
randomized controlled trial,85 in which patients in study
arm 1 are operated on only by surgeons with expertise for
the open sigmoid resection whereas patients in arm 2 are
operated on only by surgeons with expertise for the lap-
aroscopic sigmoid resection. Although this approach re-
duces the differences in surgical skills among surgeons
and thus postrandomization bias, it does not reflect the
‘‘real world’’ in which most surgeons perform both the
laparoscopic and open procedures and choose one or
another option depending on the patient.
Surgeons
Finally, a serious challenge to the performance of
clinical trials in surgery are the surgeons themselves.
First, surgeons often do not have sufficient time to invest
in the thorough design and performance of randomized
controlled studies, which may lead to poorly designed and
conducted trials that are wasteful and ethically question-
able. Second, surgeons are often not reimbursed, or only
partially reimbursed, for performing additional therapeutic
or diagnostic interventions, which renders participation to
a clinical trial less appealing. While financial support is
often readily available for pharmaceutical trials because
they are frequently funded by the pharmaceutical indus-
try, there are fewer industry sponsors of surgical re-
search. Third, a problem with randomized clinical trials in
surgery relates to the competitive culture in which sur-
geons work. Many surgeons may not agree to enroll pa-
tients in trials where the patients are assigned to a
nonoperative study arm because of competition among
surgeons to attract patients and out of fear of losing a
source of referrals.
Finally, it takes many years until results from a pro-
spective randomized clinical trial are available and an
article can be published. This delay in publishable data is
another factor that decreases the enthusiasm of some
surgeons to participate in surgical trials.
The clinical trial in surgery is a challenging undertak-
ing and if not carefully done has many pitfalls and limi-
tations. Clearly, randomized clinical trials in surgery are
not bias-free despite persistent perceptions to the con-
trary. Nonetheless, it is vitally important that surgeons
continue to perform clinical trials, which because of their
rigorous study design often represent cornerstones in
surgical research. It is critical, however, that medical
centers collaborate to accrue sufficient numbers of pa-
tients in a timely manner, that exclusion criteria are
chosen sparingly to increase the generalizability of the
results, that postrandomization bias is minimized by
standardizing surgical and diagnostic procedures, and
that surgeons collaborate with clinical researchers and
statisticians. Only then can results with the highest sci-
entific value and greatest potential patient benefit be
obtained.
CONCLUSIONS
Prospective clinical trials and retrospective outcomes
research have their respective strengths and limitations,
and both deserve a place in surgical research. Although
well designed and well conducted randomized clinical
trials provide the ‘‘gold standard’’ of scientific evidence,
especially if performed in the multicenter setting, there
exists a plethora of novel, relevant, and interesting
research questions that cannot be addressed through
randomized clinical trials because of prohibitively high
costs, long follow-up, the rarity of a specific disease, or
because the study would require ethically dubious prac-
tices. This gap, however, can be filled by surgical out-
comes research. The use of administrative databases, if
carefully planned, thoroughly performed, and cautiously
interpreted, can provide invaluable data for a variety of
research applications. Therefore, outcomes research
based on administrative databases should be viewed as
complementary and not inferior to prospective random-
ized clinical trials in surgery. Both study types play
important roles in the critical evaluation of health care
delivery and must be further explored for potential benefit
to current surgical practice. It is hoped that the present
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article stimulates surgeons to engage more actively in
surgical research using prospective randomized clinical
trials as well as retrospective outcomes research. Only
the active exploration of both investigational avenues can
maximize the result for which we all strive: improved
health care delivery.
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